HONLIV HEALTH (09906): Received resumption guidance from the Hong Kong Stock Exchange.

HONLIV HEALTH (09906) announced that on May 13, 2026, the company received a letter from the Stock Exchange listing guidelines for the resumption of trading of the company's shares on the Stock Exchange. According to the resumption guidelines, the company must: - Conduct appropriate independent forensic investigations on loans, loan income transfers to a construction company, bank transfer receipts and partial repayments made by Hongli Hospital on the loan, as well as any other loans or arrangements of a similar nature or causing similar concerns, evaluate their impact on the company's business operations and financial condition, announce investigation results and take appropriate remedial actions; - Prove that the group's management and/or any individuals with significant influence on the company's management and operations have no reasonable supervisory concerns in terms of integrity, ability and/or character, causing investors to bear risks and damage market confidence; - Engage an independent internal monitoring consultant to conduct an independent internal monitoring review and demonstrate: (i) all major deficiencies identified in relation to the suspension of trading have been corrected and all necessary remedial measures have been implemented; and (ii) the company's internal monitoring is sufficient and effective to achieve its goals and ensure compliance with the listing rules in all material respects, including but not limited to financial reporting, cash management, disclosure and compliance related to disclosure and related transactions, and significant disclosure of information; - Publish all financial performance required by the listing rules but not yet published, and address any audit revision issues; - Prove that the company complies with Rule 13.24 of the listing rules; and - Disclose all material information sufficient for shareholders and investors to assess the company's condition. The company is taking appropriate measures to comply with the resumption guidelines and will work to resume share trading as soon as possible. The company will inform shareholders and potential investors of the latest developments at the appropriate time, and will publish quarterly updates in accordance with Rule 13.24A of the listing rules.